Prometheus Competitors

Delisted . USA . 
Stock . Prometheus Biosciences
RXDXDelisted Stock  USD 199.92  0.24  0.12%   
Prometheus Biosciences competes with Apellis Pharmaceuticals, Akero Therapeutics, Immunovant, Madrigal Pharmaceuticals, and Roivant Sciences; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Prometheus Biosciences competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Prometheus Biosciences to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Prometheus Biosciences competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Prometheus Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
199.92199.92199.92
Details
Intrinsic
Valuation
LowRealHigh
150.07150.07219.91
Details

Prometheus Biosciences Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Prometheus Biosciences and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Prometheus and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Prometheus Biosciences does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
ACLX
+ 0.83
AKRO
STOK
+ 0.82
APLS
KRYS
+ 0.78
APLS
ETNB
+ 0.71
MDGL
PLRX
+ 0.65
ETNB
STOK
+ 0.61
KRYS
  
High negative correlations   
ACLX
- 0.72
APLS
AKRO
- 0.66
APLS
STOK
- 0.42
AKRO
ACLX
- 0.4
IMVT
STOK
- 0.37
ACLX
ACLX
- 0.37
KRYS

Risk-Adjusted Indicators

There is a big difference between Prometheus Stock performing well and Prometheus Biosciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Prometheus Biosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
APLS  2.39 (0.40) 0.00 (0.45) 0.00 
 0.00 
 4.31 
(5.17)
 15.97 
AKRO  2.39  0.13  0.09  0.18  2.66 
(2.51)
 5.23 
(4.45)
 13.37 
IMVT  2.02 (0.35) 0.00 (0.18) 0.00 
 0.00 
 3.76 
(5.06)
 17.16 
MDGL  2.68  0.54  0.19  1.52  2.09 
(3.60)
 5.17 
(3.96)
 30.27 
ROIV  1.34  0.01 (0.01) 0.14  1.57 
(1.34)
 2.87 
(2.52)
 7.52 
KRYS  1.82 (0.22) 0.00 (0.02) 0.00 
 0.00 
 4.45 
(3.75)
 12.05 
ETNB  2.79 (0.22) 0.00  0.04  3.29 
(3.41)
 5.19 
(6.35)
 27.43 
PLRX  2.71 (0.23)(0.03) 0.02  3.19 
(2.93)
 5.37 
(5.55)
 24.35 
ACLX  2.46  0.23  0.12  0.22  2.74 
(2.67)
 6.28 
(5.68)
 15.13 
STOK  2.63 (0.38) 0.00 (0.17) 0.00 
 0.00 
 4.68 
(6.99)
 21.35 
All Fundamental Data

Prometheus Biosciences Competitive Analysis

The better you understand Prometheus Biosciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Prometheus Biosciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Prometheus Biosciences' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
RXDX APLS AKRO IMVT MDGL ROIV KRYS ETNB PLRX ACLX
 0.12 
 199.92 
Prometheus
 3.70 
 31.91 
Apellis
 2.93 
 31.77 
Akero
 0.07 
 26.89 
Immunovant
 0.65 
 345.18 
Madrigal
 0.56 
 12.46 
Roivant
 2.18 
 194.56 
Krystal
 2.28 
 8.96 
89bio
 3.70 
 13.46 
Pliant
 1.14 
 89.41 
Arcellx
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Very steady
Very steady
Not too volatile
Very steady
Somewhat reliable
Not too volatile
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
OK
Very Weak
OK
Insignificant
Very Weak
Weak
Weak
Good
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Low
Low
Average
Low
Low
Very Low
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Under Valued
Fairly Valued
Under Valued
Over Valued
Under Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Sell
Cautious Hold
Sell
Strong Hold
Cautious Hold
Cautious Hold
Strong Sell
Strong Sell
Cautious Hold
Current Ratio
13.32
7.57
6.9
21.48
2.55
6.2
12.45
5.81
7.69
10.16
Net Asset
740.77 M
788.73 M
580.27 M
666.37 M
640.55 M
7.22 B
818.36 M
596.27 M
512.15 M
825.13 M
Profit Margin
N/A
-0.35
N/A
N/A
N/A
37.25
0.22
N/A
N/A
-0.26
EBITDA
(145.78 M)
(495.21 M)
(148.63 M)
(269.98 M)
(379.97 M)
4.31 B
17.9 M
(134.46 M)
(158.23 M)
(64.14 M)
Operating Margin
-40.65
-0.24
N/A
N/A
-1.87
-74.46
0.42
N/A
N/A
-1.29
Current Valuation
4.39 B
3.9 B
1.6 B
3.47 B
6.7 B
3.79 B
4.9 B
643.81 M
445.58 M
4.38 B
Price To Book
19.88
16.14
3.09
8.78
9.75
1.77
6.18
2.72
2.28
10.12
Retained Earnings
(331.09 M)
(2.84 B)
(574.1 M)
(825.68 M)
(1.34 B)
576.17 M
(269.83 M)
(457.43 M)
(499.75 M)
(389.48 M)
Current Asset
135.99 M
115.82 M
22.85 M
N/A
363.58 K
N/A
2.05 M
10.12 M
N/A
N/A
Beta
-0.49
0.87
-0.26
0.71
-0.47
1.24
0.82
0.98
1.09
0.27
Number Of Employees
97
702
60
207
376
908
229
70
166
130
Equity Positions Weight
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Shares Outstanding
47.81 M
124.39 M
69.8 M
146.78 M
21.81 M
727.95 M
28.76 M
117.58 M
60.85 M
54.07 M
Cash Flow From Operations
(123.25 M)
(594.74 M)
(145.37 M)
(214.23 M)
(324.23 M)
(765.27 M)
(88.8 M)
(129.19 M)
(116.36 M)
207.57 M
Total Debt
14.76 M
110.93 M
26.3 M
138 K
117.19 M
499.75 M
8.09 M
27.11 M
11.37 M
97.62 M
Return On Equity
-0.33
-1.07
-0.36
-0.92
-1.3
1.29
0.0638
-0.73
-0.48
-0.11
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.2
-0.16
-0.23
-0.55
-0.52
-0.18
0.0458
-0.41
-0.28
-0.0629
Number Of Shares Shorted
4.68 M
20.79 M
3.82 M
13.1 M
4.53 M
46.57 M
3.45 M
5.38 M
7.22 M
3.93 M
Book Value Per Share
14.62
1.94
10.61
3.06
35.64
7.03
30.81
3.56
5.68
8.95
Current Liabilities
24.54 M
5.13 M
859.05 K
N/A
49.28 M
N/A
40.74 K
3.89 M
N/A
N/A
Total Asset
740.77 M
788.73 M
580.27 M
666.37 M
640.55 M
7.22 B
818.36 M
596.27 M
512.15 M
825.13 M
Debt To Equity
0.076
0.63
0.072
0.004
0.6
0.28
0.016
0.13
0.11
0.094
Short Ratio
3.97
7.13
8.02
19.69
13.46
11.66
23.12
10.28
17.04
8.11
Target Price
190.0
45.75
48.27
48.93
372.2
16.21
207.78
30.13
40.18
111.81
Shares Owned By Institutions
81.01
97.46
94.66
54.57
91.44
79.46
87.7
93.66
97.15
93.19
Market Capitalization
9.56 B
3.83 B
2.28 B
3.94 B
7.58 B
9.12 B
5.48 B
1.03 B
789.88 M
4.89 B
Price To Earning
-5.66
-6.94
-7.43
N/A
-13.96
N/A
-6.36
-1.04
N/A
N/A
Price To Earnings To Growth
N/A
-0.3
0.93
N/A
N/A
N/A
N/A
-0.45
N/A
-0.07
Price To Sales
627.82
5.35
N/A
N/A
98.66
70.64
22.67
N/A
3050.34
31.39
Net Income
(141.75 M)
(528.63 M)
(151.76 M)
(259.34 M)
(373.63 M)
4.23 B
10.93 M
(142.19 M)
(161.34 M)
(70.69 M)
Earnings Per Share
-3.54
-2.03
-3.78
-2.21
-25.02
5.54
1.77
-2.96
-3.35
-0.71
Shares Owned By Insiders
16.61
13.98
5.34
55.64
8.56
29.55
12.3
0.57
2.85
12.62
Revenue
6.81 M
396.59 M
N/A
N/A
N/A
124.8 M
50.7 M
N/A
1.58 M
110.32 M
Working Capital
685.33 M
518.74 M
540.83 M
617.16 M
518.73 M
6.47 B
554.82 M
563.92 M
476.98 M
598.12 M
Cash And Equivalents
95.96 M
852.8 M
180.72 M
427.2 M
211.77 M
1.94 B
425.56 M
193.34 M
163.6 M
306.99 M
Cash Per Share
2.35
7.76
4.81
3.66
12.38
2.76
16.58
4.16
3.36
7.01
Gross Profit
(106.04 M)
69.79 M
N/A
N/A
N/A
(477.06 M)
N/A
N/A
9.69 M
N/A
Day Typical Price
199.83
32.02
32.27
27.07
345.81
12.6
195.2
9.12
13.49
91.39
Accumulation Distribution
0.0019
465158.0
31744.13
36510.42
13973.13
323765.0
7702.63
62202.25
29372.79
34782.85
Market Facilitation Index
0.38
N/A
0.0
0.0
0.0
N/A
0.0
0.0
0.0
0.0
Daily Balance Of Power
0.6316
0.5816
(0.61)
0.0202
(0.20)
(0.13)
0.9183
0.3333
0.48
(0.16)
Period Momentum Indicator
0.24
1.14
(0.96)
0.02
(2.27)
(0.07)
4.16
0.2
0.48
(1.03)
Rate Of Daily Change
1.0
1.04
0.97
1.0
0.99
0.99
1.02
1.02
1.04
0.99
Day Median Price
199.79
32.07
32.52
27.17
346.12
12.68
195.52
9.2
13.5
92.38
Price Action Indicator
0.25
0.41
(1.22)
(0.27)
(2.07)
(0.25)
1.13
(0.14)
0.2
(3.48)
Coefficient Of Variation
838.32
(1,111)
798.87
(1,386)
755.23
1430.7
(9,639)
3108.62
8675.22
623.49
Mean Deviation
2.4
2.39
2.39
2.02
2.68
1.34
1.82
2.79
2.71
2.46
Jensen Alpha
1.24
(0.40)
0.1302
(0.35)
0.5441
0.0118
(0.22)
(0.22)
(0.23)
0.2271
Total Risk Alpha
(0.34)
(0.85)
(0.11)
(0.64)
(0.12)
(0.16)
(0.43)
(0.52)
(0.57)
(0.0006)
Sortino Ratio
0.4957
N/A
0.086
N/A
0.1927
(0.01)
N/A
3.0E-4
(0.03)
0.1182
Downside Variance
3.36
N/A
9.13
N/A
5.96
2.95
N/A
11.54
11.23
10.83
Standard Deviation
8.71
3.41
3.12
2.75
4.54
1.73
2.48
4.1
3.82
3.24
Kurtosis
62.06
3.4
(0.26)
1.96
13.38
1.25
1.37
4.79
5.88
0.1976
Potential Upside
2.76
4.31
5.23
3.76
5.17
2.87
4.45
5.19
5.37
6.28
Treynor Ratio
(0.60)
(0.45)
0.1835
(0.18)
1.52
0.1352
(0.02)
0.0424
0.0158
0.2178
Maximum Drawdown
70.71
15.97
13.37
17.16
30.27
7.52
12.05
27.43
24.35
15.13
Variance
75.91
11.62
9.74
7.57
20.61
3.01
6.14
16.78
14.57
10.5
Market Risk Adjusted Performance
(0.59)
(0.44)
0.1935
(0.17)
1.53
0.1452
(0.01)
0.0524
0.0258
0.2278
Risk Adjusted Performance
0.1006
(0.06)
0.1035
(0.05)
0.1099
0.0592
(0)
0.0328
0.0168
0.1306
Skewness
7.76
0.4109
0.1632
0.1496
3.09
0.3507
0.7732
1.01
1.48
(0.21)
Semi Deviation
0.764
N/A
2.66
N/A
2.09
1.57
N/A
3.29
3.19
2.74
Information Ratio
0.1043
(0.13)
0.0833
(0.12)
0.1036
(0.01)
(0.06)
2.0E-4
(0.02)
0.12
Value At Risk
(3.26)
(5.17)
(4.45)
(5.06)
(3.96)
(2.52)
(3.75)
(6.35)
(5.55)
(5.68)
Expected Short fall
(2.61)
N/A
(2.51)
N/A
(3.60)
(1.34)
N/A
(3.41)
(2.93)
(2.67)
Downside Deviation
1.83
N/A
3.02
N/A
2.44
1.72
N/A
3.4
3.35
3.29
Semi Variance
0.5836
N/A
7.08
N/A
4.37
2.46
N/A
10.8
10.19
7.53

Prometheus Biosciences Competition Performance Charts

Five steps to successful analysis of Prometheus Biosciences Competition

Prometheus Biosciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Prometheus Biosciences in relation to its competition. Prometheus Biosciences' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Prometheus Biosciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Prometheus Biosciences' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Prometheus Biosciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Prometheus Biosciences position

In addition to having Prometheus Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Electronic Equipment Thematic Idea Now

Electronic Equipment
Electronic Equipment Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Electronic Equipment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Electronic Equipment Theme or any other thematic opportunities.
View All  Next Launch
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Other Consideration for investing in Prometheus Stock

If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY